Goal · Fat Loss
Peptides people talk about for fat loss.
Where peptides get most oversold — and most interesting.
Get a personalised briefingThe peptides
Graded honestly, hype deflated
Tirzepatide
An approved, dual-hormone diabetes and weight-loss medicine with some of the strongest human evidence in this entire category. The catch: 'tirzepatide' bought as grey-market powder is a completely different risk story from the prescribed drug.
Semaglutide
The GLP-1 drug that started the whole metabolic gold rush — approved, heavily studied, and not a grey-market mystery box. Branded semaglutide and grey powder sold as 'semaglutide' are not the same product, and regulators are blunt about it.
Retatrutide
An experimental Eli Lilly weight-loss drug hitting three gut-hormone receptors at once. In real trials it produced eye-watering fat loss — which is exactly why the grey market is selling unapproved copies of it.
Tesamorelin
A GHRH analog that's actually FDA-approved — for a specific condition (HIV-associated belly-fat accumulation). That approval makes it a rare high-evidence peptide, and a useful yardstick for judging everything else.
CJC-1295
A synthetic GHRH analog that tells your body to make more growth hormone. Half the GH stack, endlessly confused over 'DAC vs no-DAC,' and marketed as 'safe GH' — a phrase that's doing a lot of work.
Ipamorelin
A selective growth-hormone secretagogue, the gentle-reputation other half of the GH stack. 'Cleaner' than the older GHRPs — which people wrongly read as 'proven safe.'
Not technically peptides
The other stuff people use for this
Steroids, SARMs and secretagogues that target the same goal. Clearly tagged — same rules apply: we grade them, we don't dose them.
Apitegromab
Scholar Rock's myostatin-blocking antibody. Myostatin is the signal telling your body to limit muscle — block it, and the hope is you keep muscle you'd otherwise lose. Being tested alongside GLP-1 drugs so the weight you drop is fat, not muscle.
Bimagrumab
An antibody that blocks the activin type II receptor — the docking station myostatin uses to tell muscle to stay small. Originally a Novartis muscle drug, now owned by Eli Lilly and being tested with semaglutide for fat loss that spares (or even adds) muscle.
Trevogrumab
Regeneron's antibody against myostatin (GDF8) — the third horse in the muscle-preservation race. Being trialled alongside semaglutide, alone and paired with a second antibody, to keep weight loss from eating your muscle.